0
0
New Delhi, May 3, 2025 – In a significant stride for Indian medical science, the All India Institute of Medical Sciences (AIIMS) Delhi has pioneered a cutting-edge diagnostic technique for a rare respiratory disorder, marking a new era in high-precision medicine.
The innovative approach, developed by a multidisciplinary team at AIIMS, leverages advanced molecular and genetic testing to accurately diagnose Primary Ciliary Dyskinesia (PCD)-a rare, inherited condition that affects the respiratory tract and can lead to chronic lung infections, sinus issues, and other complications. Early and precise diagnosis of PCD has long posed a challenge due to its overlapping symptoms with more common respiratory diseases.
Revolutionizing Patient Care
Traditionally, diagnosing PCD required a combination of clinical evaluation, imaging, and invasive procedures, often resulting in delayed or inconclusive outcomes. The new AIIMS protocol integrates next-generation sequencing (NGS) and high-resolution electron microscopy, enabling clinicians to pinpoint genetic mutations and structural abnormalities in cilia with unprecedented accuracy.
Dr. Randeep Guleria, former Director of AIIMS and a leading pulmonologist, commented, “This high-precision diagnostic method is a game-changer. It not only shortens the time to diagnosis but also ensures that patients receive the most appropriate and timely treatment, improving long-term outcomes.”
Hope for Patients and Families
PCD, though rare, can have a profound impact on quality of life. Early diagnosis is crucial for managing symptoms and preventing irreversible lung damage. The AIIMS breakthrough is expected to benefit hundreds of undiagnosed patients across India and may serve as a model for other rare diseases.
The team at AIIMS is now working to make this diagnostic tool more widely available, collaborating with regional hospitals and training healthcare professionals in its use.
Looking Ahead
This achievement underscores India’s growing expertise in precision medicine and the commitment of its premier institutions to address complex healthcare challenges. As research continues, AIIMS aims to further refine the technique and explore its application to other rare genetic disorders.
Disclaimer:
This article is based on information available from eMediNexus and related news sources as of May 3, 2025. The details provided are for informational purposes only and should not be considered as medical advice. For diagnosis and treatment of any medical condition, please consult a qualified healthcare professional.
Citations:
